ಟ್ವೀಟ್‌ಗಳು

ನೀವು @RebeccaDRobbins ಅವರನ್ನು ತಡೆಹಿಡಿದಿರುವಿರಿ

ಈ ಟ್ವೀಟ್‌ಗಳನ್ನು ವೀಕ್ಷಿಸಲು ನೀವು ಖಚಿತವಾಗಿ ಬಯಸುವಿರಾ? ಟ್ವೀಟ್ ವೀಕ್ಷಣೆಯು @RebeccaDRobbins ಅವರ ತಡೆತೆರವುಗೊಳಿಸುವುದಿಲ್ಲ

  1. ಪಿನ್ ಮಾಡಿದ ಟ್ವೀಟ್
    ಅಕ್ಟೋ 25

    Hi, friends! Some exciting news: I am starting a weekly newsletter covering biotech and life sciences happenings on the West Coast. It is called GO WEST. Sign up to get it in your inbox every Wednesday morning, starting Nov. 14:

    ಈ ಥ್ರೆಡ್ ತೋರಿಸಿ
    ರದ್ದುಗೊಳಿಸು
  2. ಅವರು ಮರುಟ್ವೀಟಿಸಿದ್ದಾರೆ
    2 ಗಂಟೆಗಳ ಹಿಂದೆ

    Excited for my podcasting debut on The Readout LOUD! I'll be talking about IBM Watson's struggles in health care. Get excited & read the latest installment in my & 's investigation into the company, for :

    ರದ್ದುಗೊಳಿಸು
  3. 3 ಗಂಟೆಗಳ ಹಿಂದೆ

    Just finished recording the final ep of 2018 of our biotech podcast. Ep will drop later this afternoon. Our guests this week: 🔹Ed Kaye, on his new biotech startup and his tenure as Sarepta CEO 🔹, on IBM's Watson Health business in China

    ರದ್ದುಗೊಳಿಸು
  4. ಅವರು ಮರುಟ್ವೀಟಿಸಿದ್ದಾರೆ
    24 ಗಂಟೆಗಳ ಹಿಂದೆ

    First trial results of cancer vaccines in glioblastoma: Researchers found they could induce an immune response, but no clinical difference made via

    ರದ್ದುಗೊಳಿಸು
  5. 23 ಗಂಟೆಗಳ ಹಿಂದೆ

    The latest edition of ' West Coast newsletter features news from & more: Sign up to get GO WEST in your inbox every Wednesday morning:

    ರದ್ದುಗೊಳಿಸು
  6. 23 ಗಂಟೆಗಳ ಹಿಂದೆ
    ರದ್ದುಗೊಳಿಸು
  7. ಡಿಸೆಂ 19

    I wrote about a fight between the University of California and the publisher Elsevier that could shape how academic research gets read and published.

    ರದ್ದುಗೊಳಿಸು
  8. ಅವರು ಮರುಟ್ವೀಟಿಸಿದ್ದಾರೆ
    ಡಿಸೆಂ 19

    I took a look at Vas Narasimhan's first year at . A few thoughts, including what he learned from the Michael Cohen affair and what's up for AveXis and gene therapy.

    ರದ್ದುಗೊಳಿಸು
  9. ಅವರು ಮರುಟ್ವೀಟಿಸಿದ್ದಾರೆ
    ಡಿಸೆಂ 19

    First at STAT: wants answers from Pfizer on price hikes for its nerve pain drug, Lyrica.

    ರದ್ದುಗೊಳಿಸು
  10. ಡಿಸೆಂ 19

    At 23andMe, taking calls from people who just got a life-changing surprise is so stressful that customer service reps are encouraged to go for a walk after an intense call, or crack open a bottle of wine. Great story via

    ರದ್ದುಗೊಳಿಸು
  11. ಅವರು ಮರುಟ್ವೀಟಿಸಿದ್ದಾರೆ
    ಡಿಸೆಂ 19

    IBM Watson is struggling in China - hospitals are delaying use of the technology after and I reported for that a cancer care software might give unsafe advice. Our latest:

    ರದ್ದುಗೊಳಿಸು
  12. ಡಿಸೆಂ 19
    ರದ್ದುಗೊಳಿಸು
  13. ಡಿಸೆಂ 18

    As you firm up your plans, consider blocking off Wednesday Jan. 9 4:30-5:15 pm for a conversation with , , and me at the Hilton San Francisco in Union Square. It's free to attend!

    ರದ್ದುಗೊಳಿಸು
  14. ಡಿಸೆಂ 18

    Scientists are newly hopeful that breast milk might yield an exciting array of therapies. has the very cool story:

    ರದ್ದುಗೊಳಿಸು
  15. ಡಿಸೆಂ 18
    ರದ್ದುಗೊಳಿಸು
  16. ಡಿಸೆಂ 18
    ರದ್ದುಗೊಳಿಸು
  17. ಡಿಸೆಂ 18

    I highly recommend 's beautifully-written new series on a family's quest to get gene therapy for their son with a rare inherited muscular disease. Story highlights tensions between a biotech and a clinical trial site that aren't often public

    ರದ್ದುಗೊಳಿಸು
  18. ಅವರು ಮರುಟ್ವೀಟಿಸಿದ್ದಾರೆ
    ಡಿಸೆಂ 17

    Our tick-tock of He Jiankui & the years leading up to the birth of . One nugget: In October, leading experts thought they could bring He into line. But the twins were a month away from being born

    ರದ್ದುಗೊಳಿಸು
  19. ಅವರು ಮರುಟ್ವೀಟಿಸಿದ್ದಾರೆ
    ಡಿಸೆಂ 17

    The Trump administration wants to research "alternatives" to human fetal tissue. That's a vague word. What does it mean? Mine for :

    ರದ್ದುಗೊಳಿಸು
  20. ಅವರು ಮರುಟ್ವೀಟಿಸಿದ್ದಾರೆ
    ಡಿಸೆಂ 17

    How in the world did we get ? He Jiankui was networking like mad & dropping hints since 2016. The backstory of how he crossed paths w/the CRISPR elite & how they tried (or didn't) to stop him:

    ರದ್ದುಗೊಳಿಸು
  21. ಅವರು ಮರುಟ್ವೀಟಿಸಿದ್ದಾರೆ
    ಡಿಸೆಂ 15

    My view on polygenic risk scores at : When risk models, like PRS, are built from risk factors, it is no surprise that they predict or that the highest XX% has a YY-fold risk compared to the rest. The question is: does PRS predict good enough to deliver utility?

    ರದ್ದುಗೊಳಿಸು

ಲೋಡಿಂಗ್ ಸಮಯ ಸ್ವಲ್ಪ ತೆಗೆದುಕೊಳ್ಳುತ್ತಿರುವಂತೆನಿಸುತ್ತದೆ.

Twitter ಸಾಮರ್ಥ್ಯ ಮೀರಿರಬಹುದು ಅಥವಾ ಕ್ಷಣಿಕವಾದ ತೊಂದರೆಯನ್ನು ಅನುಭವಿಸುತ್ತಿರಬಹುದು. ಮತ್ತೆ ಪ್ರಯತ್ನಿಸಿ ಅಥವಾ ಹೆಚ್ಚಿನ ಮಾಹಿತಿಗೆ Twitter ಸ್ಥಿತಿಗೆ ಭೇಟಿ ನೀಡಿ.

    ಇದನ್ನೂ ಸಹ ನೀವು ಇಷ್ಟಪಡಬಹುದು

    ·